Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

krka, d.d., novo mesto, novo mesto slovinsko - 9374 ramipril; 12990 amlodipin-besilÁt - tvrdá tobolka - 10mg/10mg - ramipril a amlodipin

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

krka, d.d., novo mesto, novo mesto array - 9374 ramipril; 12990 amlodipin-besilÁt - tvrdá tobolka - 10mg/5mg - ramipril a amlodipin

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

krka, d.d., novo mesto, novo mesto array - 9374 ramipril; 12990 amlodipin-besilÁt - tvrdá tobolka - 5mg/10mg - ramipril a amlodipin

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

krka, d.d., novo mesto, novo mesto slovinsko - 9374 ramipril; 12990 amlodipin-besilÁt - tvrdá tobolka - 5mg/5mg - ramipril a amlodipin

Evropská unie - čeština - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinurie, paroxysmální - selektivní imunosupresiva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

ratiopharm gmbh, ulm array - 13774 telmisartan - tableta - 80mg - telmisartan

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

farmak international sp.z.o.o., varšava array - 13774 telmisartan - tableta - 40mg - telmisartan

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

farmak international sp.z.o.o., varšava array - 13774 telmisartan - tableta - 80mg - telmisartan

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

sandoz s.r.o., praha array - 13774 telmisartan - tableta - 80mg - telmisartan

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

teva b.v., haarlem array - 13774 telmisartan; 12990 amlodipin-besilÁt - tableta - 40mg/5mg - telmisartan a amlodipin